FDA Clearance Tracker · P940015-S011
SYNVISC HYLAN G-F 20
Last checked: Nov 20, 2026Latest source record: Jun 9, 2008 (this decision)Source: openFDAMethods & limitations
Decided
Jun 9, 2008
Approved
Time to decision
475 days
Received Feb 20, 2007. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P940015-S011
- Device name
- SYNVISC HYLAN G-F 20
- Applicant
- Sanofi Genzyme Corp.
- Applicant location
- Cambridge, MA
- Received
- Feb 20, 2007
- Decided
- Jun 9, 2008
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P940015
Device type
- Device type
- Acid, hyaluronic, intraarticular (MOZ)
- Device class
- Class III
- Specialty
- Orthopedic Surgery
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE REPLACEMENT OF THE DILUTION STATEMENT FROM THE ?PRECAUTION? SECTION AND IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE NONPHARMACOLOGIC THERAPY AND TO SIMPLE ANALGESICS, E.G., ACETAMINOPHEN.
Source documents
Other decisions for Sanofi Genzyme Corp.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.